TipRanks (Mon, 1-Jun 9:30 AM ET)
Stifel Nicolaus Sticks to Their Buy Rating for Compass Therapeutics (CMPX)
TipRanks (Mon, 1-Jun 8:40 AM ET)
Compass Therapeutics to Participate in Upcoming June Investor Events
Globe Newswire (Thu, 28-May 7:30 AM ET)
Globe Newswire (Thu, 21-May 5:00 PM ET)
Globe Newswire (Tue, 19-May 6:09 PM ET)
Compass Therapeutics to Participate in Upcoming May Investor Events
Globe Newswire (Tue, 12-May 7:30 AM ET)
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Globe Newswire (Tue, 5-May 7:30 AM ET)
Market Chameleon (Tue, 28-Apr 6:34 AM ET)
Globe Newswire (Mon, 27-Apr 1:00 PM ET)
Market Chameleon (Mon, 27-Apr 3:51 AM ET)
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Compass Therapeutics trades on the NASDAQ stock market under the symbol CMPX.
As of June 2, 2026, CMPX stock price declined to $2.08 with 4,953,065 million shares trading.
CMPX has a beta of 0.59, meaning it tends to be less sensitive to market movements. CMPX has a correlation of 0.00 to the broad based SPY ETF.
CMPX has a market cap of $374.58 million. This is considered a Small Cap stock.
Last quarter Compass Therapeutics reported $0 in Revenue and -$.10 earnings per share. This beat revenue expectation by $642,860 and met earnings estimates .
In the last 3 years, CMPX traded as high as $6.88 and as low as $.77.
The top ETF exchange traded funds that CMPX belongs to (by Net Assets): XBI, VTI, IWM, VXF, FESM.
CMPX has underperformed the market in the last year with a return of -1.0%, while the SPY ETF gained +30.1%. In the last 3 month period, CMPX fell short of the market, returning -63.2%, while SPY returned +11.0%. However, in the most recent 2 weeks CMPX has outperformed the stock market by returning +13.7%, while SPY returned +2.8%.
CMPX support price is $2.09 and resistance is $2.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMPX shares will trade within this expected range on the day.